3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Sarcoma
1
CNS
1
Conditions
Glioma
2
Glioblastoma
2
Brain Neoplasms
2
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms
1
Gliosarcoma
1
Disease
1
Interventions
Temozolomide
19
Bevacizumab
14
Irinotecan
12
Carboplatin
10
Cyclophosphamide
9
Radiosurgery
8
Lomustine
8
Radiotherapy
7
pembrolizumab
6
Vincristine
6
Topotecan
6
Drug Therapy
6
Surgical Procedures, Operative
5
Etoposide
5
Doxorubicin
5
Cisplatin
5
3-Iodobenzylguanidine
5
trametinib
4
Metformin
4
Gemcitabine
4
Dexamethasone
4
Blood Specimen Collection
4
poly ICLC
3
dabrafenib
3
Vorinostat
3
Trastuzumab
3
Therapeutics
3
Radiation
3
Paclitaxel
3
Observation
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Antibodies, Monoclonal
×
CNS
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled